Biotech developing small molecules to inhibit necroptosis and ferroptosis in acute and chronic diseases.
| Date | Round | Amount |
|---|---|---|
| Oct 2025 | Seed SeaBeLife raised €2 million in a pre-Series A round led by iXLife to start clinical trials in dry AMD and acute hepatitis. | $2.3M |
| Apr 2024 | Grant French biotech SeaBeLife won over €1.5M for its SeaBeEYE project via the i-Nov 2024 competition (France 2030 / Bpifrance) to develop drugs for advanced AMD. | $1.6M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.